Home › Funds › Atle Fund Management AB › KRYS

Atle Fund Management AB position in KRYS

KRYSTAL BIOTECH INC · Health Care

Atle Fund Management AB reported holding 28,074 shares of KRYS (KRYSTAL BIOTECH INC) in its Q3 2026 13F filing — a position valued at US$9.3M, representing 2.50% of its reported portfolio and ranking #18 among its reported holdings. Atle Fund Management AB has disclosed KRYS holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)28.07K sh
Reported value held$9.34M
Portfolio Weight2.50%
First reportedQ4 2023
Last changeAdd
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Atle Fund Management AB's KRYS position evolved

Atle Fund Management AB first disclosed a stake in KRYS in Q4 2023 at 6,624 shares (US$822K). The position peaked in Q3 2026 at 28,074 shares, worth US$9.3M. Across 12 filings, Atle Fund Management AB increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 28,074 shares valued at US$9.3M — an increase of 4,055 shares quarter over quarter.. Notable position changes include a 155% increase in Q1 2025 (shares fell 24% over the following quarter), a 109% increase in Q3 2025 (shares rose 40% over the following quarter), a 36% trim in Q2 2026 (shares fell 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 6.62K $821.77K New
Q1 2024 6.62K $1.18M Hold
Q2 2024 7.62K $1.40M Add
Q3 2024 9.20K $1.68M Add
Q4 2024 9.20K $1.47M Hold
Q1 2025 23.49K $4.24M Add
Q2 2025 20.16K $2.77M Reduce
Q3 2025 42.19K $790.71K Add
Q4 2025 33.85K $8.35M Reduce
Q1 2026 37.58K $6.79M Add
Q2 2026 24.02K $8.93M Reduce
Q3 2026 28.07K $9.34M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KRYS and 13F data

KRYS (KRYSTAL BIOTECH INC) is a Health Care company. 49 other funds we track also report a position in KRYS — the largest reported positions include Avoro Capital Advisors LLC (US$1.07B), Soleus Capital Management, L.P. (US$349.1M), Hood River Capital Management LLC (US$246.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KRYS

All KRYS fund holders →

FAQ

How long has Atle Fund Management AB held KRYS?

Atle Fund Management AB has disclosed KRYS holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Atle Fund Management AB's current position in KRYS?

As of Q3 2026, Atle Fund Management AB holds 28.07K shares of KRYS (KRYSTAL BIOTECH INC), valued at $9.34M, representing 2.50% of its reported portfolio and ranking #18.

Has Atle Fund Management AB been buying or selling KRYS?

In the latest 13F filing (Q3 2026), Atle Fund Management AB increased its position in KRYS. The position peaked in Q3 2026 at 28.07K shares.

Which other funds hold KRYS?

Other major institutional holders of KRYS include Avoro Capital Advisors LLC, Soleus Capital Management, L.P., Hood River Capital Management LLC, among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.